Shanghai Sigma Audley SSA Semaglutide

As of 9 Aug 2026, Finnrick has published 10 independent lab tests of Semaglutide from Shanghai Sigma Audley SSA: 8 passed and 2 failed under the default public standard, Purity Focus (HPLC purity at least 99.5%, fill within ±35% of the label claim). The latest test is dated 3 Mar 2026. The current Finnrick rating for Shanghai Sigma Audley SSA Semaglutide is 75%.

Finnrick ratings are recency-weighted pass percentages: newer tests count more, and vendors with thin test histories are pulled toward the peer baseline for that peptide, so a single result cannot look too certain. Samples are analyzed by independent partner laboratories and the results are published by Finnrick Analytics, which does not sell peptides and does not accept payment to alter ratings. Corrections to published data are recorded at finnrick.com/corrections.

Interactive charts, prices, and test history for this page load with JavaScript; the facts above are from Finnrick's published test database.

Published lab tests of Semaglutide from Shanghai Sigma Audley SSA, newest first.
DateResultCertificate
3 Mar 2026PassCertificate gzxr9z4
30 Oct 2025FailCertificate nmmty5s
21 Oct 2025PassCertificate gwt2jeb
2 Oct 2025PassCertificate k4kkek5
18 Sep 2025PassCertificate xajcawj
4 Sep 2025PassCertificate u4s6uhb
1 Sep 2025PassCertificate vtt8hfp
21 Aug 2025PassCertificate 2v86ud2
11 Aug 2025PassCertificate hvjkn5y
29 Jun 2025FailCertificate zbgk4f2